L-citrulline Enriched Fermented Milk with Lactobacillus helveticus Attenuates Dextran Sulfate Sodium (DSS) Induced Colitis in Mice.
- 2022-01
- The Journal of Nutritional Biochemistry 99
- Sze Wing Ho
- H. El‐Nezami
- H. Corke
- C. Ho
- N. Shah
- PubMed: 34587540
- DOI: 10.1016/j.jnutbio.2021.108858
Abstract
Inflammatory bowel disease (IBD) is a group of chronic inflammatory gastrointestinal diseases that causes worldwide suffering. L. helveticus is a probiotic that can enhance intestinal barrier function via alleviation of excessive inflammatory response. Citrulline, a functional amino acid, has been reported to stimulate muscle synthesis and to function with a prebiotic-like action with certain Lactobacillus strains. The aim of this study was to investigate the potential synergistic effect of combining L. helveticus and citrulline on protection against damage induced by dextran sulfate sodium (DSS) in a mouse model. 6-week-old male C57BL/6J mice were fed with DSS water and randomly divided for administering with different milk treatments: 1) plain milk (control or DSS control), 2) 1% (w/v) citrulline enriched milk (Cit_milk), 3) milk fermented with L. helveticus (LHFM) and 4) DSS+milk fermented with L. helveticus with 1% (w/v) citrulline (Cit_LHFM). The treatment effects on the survival and macroscopic and microscopic signs were examined. All treatments presented different degrees of protective effects on attenuating the damages induced by DSS. All treatments reduced the body weight loss, disease activity index (DAI), histological scores, pro-inflammatory cytokine expression (IL-6, TNF-α and IFN-γ) and production (IL-4) (all P <0.05) and the tight junction (TJ) protein (zonula occluden-1 (ZO-1) expression. LHFM and Cit_LHFM improved survival rate (both at P<0.05). Particularly, Cit_LHFM showed greater effects on protecting the damages induced by DSS, especially in ameliorating colonic permeability, TJ protein (ZO-1, occludin and claudin-1) expression and distribution as well as in reducing IL-4 and IL-17 expression (all P <0.05). Our findings suggested that the combination of and citrulline had significant synergistic effect on protecting against injury from DSS-induced colitis. Therefore, citrulline enriched L. helveticus fermented milk is suggested to be a potential therapy for treating IBD.
Keywords: Dextran sulfate sodium induced colitis; L-citrulline; L. helveticus; fermented milk with La. helveticus; inflammation; tight junction proteins.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus helveticus | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus | Reduced Disease Activity | Beneficial | Moderate |
Lactobacillus helveticus | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus HA-128 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus HA-128 | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus HA-128 | Reduced Disease Activity Index (DAI) Levels | Beneficial | Moderate |
Lactobacillus helveticus L10 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus L10 | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus L10 | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus L10 | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus L10 | Reduced Disease Activity Index (DAI) Levels | Beneficial | Moderate |
Lactobacillus helveticus L10 | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus L10 | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus LH76 | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus LH76 | Reduced Disease Activity Index (DAI) Levels | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Reduced IL-17 Expression | Beneficial | Large |
Lactobacillus helveticus LH76 | Reduced Interleukin-4 Production | Beneficial | Moderate |
Lactobacillus helveticus LH76 | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus R0052 | Improved Disease Activity Index Score | Beneficial | Moderate |
Lactobacillus helveticus R0052 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus R0052 | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus R0052 | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus R0052 | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus R0052 | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus Rosell-52 | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus Rosell-52 | Reduced Disease Activity | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Reduced IL-17 Expression | Beneficial | Large |
Lactobacillus helveticus Rosell-52 | Reduced Interleukin-4 Production | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus Rosell-52 ME | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus Rosell-52 ME | Reduced Disease Activity | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Reduced IL-17 Expression | Beneficial | Large |
Lactobacillus helveticus Rosell-52 ME | Reduced Interleukin-4 Production | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52 ME | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52ND | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52ND | Improved Tight Junction Protein Expression | Beneficial | Large |
Lactobacillus helveticus Rosell-52ND | Reduced Body Weight | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52ND | Reduced Colonic Permeability | Beneficial | Large |
Lactobacillus helveticus Rosell-52ND | Reduced Disease Activity | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52ND | Reduced Histological Scores | Beneficial | Moderate |
Lactobacillus helveticus Rosell-52ND | Reduced Pro-Inflammatory Cytokines | Beneficial | Moderate |
Lactobacillus helveticus VPro 13 | Improved Intestinal Barrier Function | Beneficial | Large |
Lactobacillus helveticus VPro 13 | Improved Survival Rate | Beneficial | Moderate |
Lactobacillus helveticus VPro 13 | Reduced Colonic Damage | Beneficial | Large |
Lactobacillus helveticus VPro 13 | Reduced Inflammation Levels | Beneficial | Large |